| Fiscal Year End | Company Status | Exempt Flag |
| September 30 | Trading | N |
|
|
|
|
|
| Incorporation Locations |
| Inc. Date | Expiry Date | Country | Region | Description |
| 4/Mar/1983 | | Canada | | |
|
|
| Exchange Filing Office |
| Location |
| Toronto Regional Service Office |
|
|  |
| Business Type(s) |
| Primary/Secondary | Business Type | Details |
| Primary
| Research and Development of Pharmaceutical Products
| News Release February 19, 2015-Arch Biopartners is a portfolio based biotechnology company established to develop new products and technology for unmet medical needs. The Company?s lead technology is MetaMx. Arch intends to perform a human trial to characterize the safety and pharmacokinetics of MetaMx and to demonstrate the efficacy of MetaMx to cross the human blood brain barrier and detect BTICs and invasive glioma cells. Such results in human patients will increase the value of MetaMx not only as a diagnostic and imaging tool but also as a potential drug delivery platform to destroy BTICs and invasive glioma cells.
|
|
|
| Securities |
| Symbol | Security Name | Market | Status |
| ARCH | Arch Biopartners Inc. | TSX Venture | TRADING |
|
|
| Name History | From | To |
| Arch Biopartners Inc. | 15/Apr/2014 | Present |
|
|
| Company Facts Reconciliation |
| Subject | Date Returned |
| Spring 2015 CFR | Not Received |
|
|
|
|
|
